Importer of Controlled Substances: Notice of Registration; Fisher Clinical Services, Inc., 23958 [2013-09537]

Download as PDF 23958 Federal Register / Vol. 78, No. 78 / Tuesday, April 23, 2013 / Notices CFR § 1301.34(b), (c), (d), (e), and (f) are satisfied. DEPARTMENT OF JUSTICE Dated: April 16, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Manufacturer of Controlled Substances; Notice of Application; Research Triangle Institute [FR Doc. 2013–09538 Filed 4–22–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration mstockstill on DSK4VPTVN1PROD with NOTICES Importer of Controlled Substances: Notice of Registration; Fisher Clinical Services, Inc. By Notice dated November 27, 2012, and published in the Federal Register on December 5, 2012, 77 FR 72409, Fisher Clinical Services, Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of Levorphanol (9220), a basic class of controlled substance in schedule II. The company plans to import the listed substances for analytical research and clinical trials. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and § 952(a), and determined that the registration of Fisher Clinical Services, Inc., to import the basic class of controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated Fisher Clinical Services, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems; verification of the company’s compliance with state and local laws; and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and § 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed. Dated: April 16, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–09537 Filed 4–22–13; 8:45 am] BILLING CODE 4410–09–P VerDate Mar<15>2010 17:51 Apr 22, 2013 Jkt 229001 Drug Enforcement Administration Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 26, 2013, Research Triangle Institute, Poonam G. Pande, Ph.D., RPH, RAC, Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle Park, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Schedule Marihuana (7360) ......................... Cocaine (9041) ............................. I II The Institute will manufacture marihuana, and cocaine derivatives for use by their customers in analytical kits, reagents, and reference standards as directed by the National Institute on Drug Abuse. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than June 24, 2013. Dated: April 16, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. (DEA) to be registered as a bulk manufacturer of Carfentanil (9743), a basic class of controlled substance listed in schedule II. The company plans to manufacture the above listed controlled substance for sale to veterinary pharmacies, zoos, and for other animal and wildlife applications. Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than June 24, 2013. Dated: April 16, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–09535 Filed 4–22–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration; S & B Pharma Inc. By Notice dated May 31, 2012, and published in the Federal Register on June 8, 2012, 77 FR 34073, S & B Pharma Inc., 405 South Motor Avenue, Azusa, California 91702–3232, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Schedule [FR Doc. 2013–09533 Filed 4–22–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application; Wildlife Laboratories, Inc. Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 7, 2013, Wildlife Laboratories Inc., 1230 W. Ash Street, Suite D, Windsor, Colorado 80550, made application by renewal to the Drug Enforcement Administration PO 00000 Frm 00076 Fmt 4703 Sfmt 4703 Gamma Hydroxybutyric Acid (2010). Tetrahydrocannabinols (7370) ..... Methamphetamine (1105) ............ Pentobarbital (2270) ..................... Nabilone (7379) ............................ I I II II II The company plans to manufacture bulk controlled substances for use in product development and for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of S & B Pharma Inc., to manufacture the listed basic classes of controlled substances is consistent with the public E:\FR\FM\23APN1.SGM 23APN1

Agencies

[Federal Register Volume 78, Number 78 (Tuesday, April 23, 2013)]
[Notices]
[Page 23958]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-09537]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances: Notice of Registration; Fisher 
Clinical Services, Inc.

    By Notice dated November 27, 2012, and published in the Federal 
Register on December 5, 2012, 77 FR 72409, Fisher Clinical Services, 
Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106, made 
application to the Drug Enforcement Administration (DEA) to be 
registered as an importer of Levorphanol (9220), a basic class of 
controlled substance in schedule II.
    The company plans to import the listed substances for analytical 
research and clinical trials.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and Sec.  952(a), and determined that 
the registration of Fisher Clinical Services, Inc., to import the basic 
class of controlled substance is consistent with the public interest 
and with United States obligations under international treaties, 
conventions, or protocols in effect on May 1, 1971. DEA has 
investigated Fisher Clinical Services, Inc., to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems; verification of the company's compliance 
with state and local laws; and a review of the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 952(a) and Sec.  958(a), and in 
accordance with 21 CFR 1301.34, the above named company is granted 
registration as an importer of the basic class of controlled substance 
listed.

    Dated: April 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-09537 Filed 4-22-13; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.